Cargando…
Type II CRISPR/Cas9 approach in the oncological therapy
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a prokaryotic adaptable immune mechanism used by many bacteria and archaea to protect themselves from foreign nucleic acids. This complex system can recognize and cut non-self DNA in order to provide the prokaryotic organisms a st...
Autores principales: | Biagioni, A., Chillà, A., Andreucci, E., Laurenzana, A., Margheri, F., Peppicelli, S., Del Rosso, M., Fibbi, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472952/ https://www.ncbi.nlm.nih.gov/pubmed/28619109 http://dx.doi.org/10.1186/s13046-017-0550-0 |
Ejemplares similares
-
Publisher Correction to: delivery systems of CRISPR/Cas9-based cancer gene therapy
por: Biagioni, Alessio, et al.
Publicado: (2019) -
Delivery systems of CRISPR/Cas9-based cancer gene therapy
por: Biagioni, Alessio, et al.
Publicado: (2018) -
CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines
por: Biagioni, Alessio, et al.
Publicado: (2021) -
EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019) -
Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis
por: Chillà, Anastasia, et al.
Publicado: (2018)